Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

279.84 +1.94 (+0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Synchronicity: Denying The Unexplainable
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph? 
Via Talk Markets
Topics Stocks / Equities
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
Looking Into Amgen's Recent Short Interest
Via Benzinga
Amgen Unusual Options Activity For February 12
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Earnings Summary: Amgen Q4
Via Benzinga
Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble?
In after-hours trades, Amgen stock fell around 2% following its fourth-quarter beat. 
Via Investor's Business Daily
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. 
Via StockStory
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Via The Motley Fool
3 Fabulous Dividend Stocks to Buy in February
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. 
Via StockStory
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Stay informed with the top movers within the S&P500 index on Wednesday.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Why Amgen (AMGN) Stock Is Trading Up Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter,... 
Via StockStory
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025. 
Via Benzinga
Topics Earnings
Exposures Financial
Earnings Miss? Amgen’s Dividend Still a Bright Spot
Via MarketBeat
Exposures Product Safety
Amgen (AMGN) Q4 2024 Earnings Call Transcript
AMGN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth. 
Via The Motley Fool
Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance of... 
Via StockStory
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025
Via The Motley Fool
Topics Stocks
Exposures US Equities
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies. 
Via Benzinga
Earnings Scheduled For February 4, 2025
Via Benzinga
Markets React To Softening Trade Tariff Policy
Monday’s trading session resulted in slight negative closes across major indexes, but there’s good news here: whereas the Dow finished the trading day -122 points, it was -400 a half hour before this... 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
The Dogs Of The Dow 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.